ATE385498T1 - Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen - Google Patents

Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen

Info

Publication number
ATE385498T1
ATE385498T1 AT01957425T AT01957425T ATE385498T1 AT E385498 T1 ATE385498 T1 AT E385498T1 AT 01957425 T AT01957425 T AT 01957425T AT 01957425 T AT01957425 T AT 01957425T AT E385498 T1 ATE385498 T1 AT E385498T1
Authority
AT
Austria
Prior art keywords
compounds
inhibitors
useful
tyrosine kinases
diseases
Prior art date
Application number
AT01957425T
Other languages
English (en)
Inventor
Roger Snow
Donghong Gao
Daniel Goldberg
Abdelhakim Hammach
Daniel Kuzmich
Tina Morwick
Neil Moss
Iii Anthony Prokopowicz
Robert Selliah
Hidenori Takahashi
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE385498T1 publication Critical patent/ATE385498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT01957425T 2000-08-11 2001-08-02 Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen ATE385498T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22472400P 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
ATE385498T1 true ATE385498T1 (de) 2008-02-15

Family

ID=22841899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957425T ATE385498T1 (de) 2000-08-11 2001-08-02 Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen

Country Status (9)

Country Link
US (2) US6489328B2 (de)
EP (1) EP1309596B1 (de)
JP (1) JP5000068B2 (de)
AT (1) ATE385498T1 (de)
CA (1) CA2417635C (de)
DE (1) DE60132702T2 (de)
ES (1) ES2299501T3 (de)
MX (1) MXPA03001306A (de)
WO (1) WO2002014319A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536533A (ja) * 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
JP4629576B2 (ja) * 2002-08-14 2011-02-09 アボット・ラボラトリーズ 中枢神経系活性剤であるアザビシクロ化合物
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20110050745A (ko) * 2002-10-03 2011-05-16 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
ME00142B (me) 2003-05-22 2010-10-10 Nerviano Medical Sciences Srl Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1809614B1 (de) * 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazin-kinasehemmer
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
EP2457901A1 (de) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazolderivate, Zusammensetzungen und Verfahren zur Verwendung als b-Sekretase-Inhibitoren
EP1858521A4 (de) * 2005-03-15 2011-07-06 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US8541457B2 (en) * 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
US7713966B2 (en) 2006-11-20 2010-05-11 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US8865742B2 (en) * 2010-11-28 2014-10-21 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
RU2652638C2 (ru) 2010-12-17 2018-04-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
KR101934651B1 (ko) * 2017-10-19 2019-01-02 가톨릭대학교 산학협력단 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR65025B (en) 1977-07-21 1980-06-16 Thomae Gmbh Dr K Method for the preparation of new imidazo-isokinolin-diones
DE3855327D1 (de) * 1987-12-30 1996-07-04 Orion Yhtymae Oy Heterocyclische Verbindungen
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0946523A1 (de) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Kondensierte polycyclische 2-aminopyrimidinderivate, ihre herstellung und verwendung als proteininhibitoren von tyrosinkinase
EP0991628B1 (de) 1997-05-28 2005-01-12 Aventis Pharmaceuticals Inc CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN
DE69833224T2 (de) 1997-11-10 2006-09-28 Bristol-Myers Squibb Co. Benzothiazole als protein tyrosin-kinase inhibitoren

Also Published As

Publication number Publication date
WO2002014319A3 (en) 2002-08-01
DE60132702T2 (de) 2009-03-19
EP1309596A2 (de) 2003-05-14
US6844435B2 (en) 2005-01-18
MXPA03001306A (es) 2003-10-15
CA2417635C (en) 2008-02-05
JP5000068B2 (ja) 2012-08-15
US20030207902A1 (en) 2003-11-06
US20020119975A1 (en) 2002-08-29
CA2417635A1 (en) 2002-02-21
US6489328B2 (en) 2002-12-03
DE60132702D1 (de) 2008-03-20
ES2299501T3 (es) 2008-06-01
EP1309596B1 (de) 2008-02-06
JP2004506636A (ja) 2004-03-04
WO2002014319A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
ATE385498T1 (de) Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
ATE277044T1 (de) Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
ATE449764T1 (de) Cytokine, insbesondere tnf-alpha, hemmer
IN2014DN06567A (de)
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE190978T1 (de) 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
DE602005024274D1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
MEP3808A (xx) Derivati pirimidinil aril uree kao fgf inhibitori
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
TW200508225A (en) Cytokine inhibitors
ATE240328T1 (de) Substituierte azaoxindolederivate
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EA200800017A1 (ru) Алкилхинолиновые и алкилхиназолиновые модуляторы киназы
EA200800015A1 (ru) Аминопиримидины в качестве модуляторов киназы
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
ATE501128T1 (de) 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1309596

Country of ref document: EP